



**San Francisco
Health Plan**

Pharmacy Services

San Francisco Health Plan Pharmacy & Therapeutics Committee

Wednesday, July 15, 2026

7:30AM – 9:30AM

50 Beale St., 13th Floor, San Francisco, CA 94119

Meeting called by:	Steve O'Brien, MD	Minutes: Luke Nelson (SFHP Pharmacy Operations Program Manager)
Meeting Objective:	Vote on proposed formulary and prior authorization (PA) criteria changes	Type of meeting: Quarterly
Member Votes Cast:	Committee Chair: Steve O'Brien, MD (SFHP Chief Medical Officer) Voting Members: Brian Ellsworth, PharmD (SFHP Pharmacy Director) James Lee, MD Nicholas Jew, MD Linda Truong, PharmD Jamie Ruiz, MD Ronald Ruggiero, PharmD Robert (Brad) Williams, MD	Others in Attendance: Eileen Kim, PharmD (SFHP Clinical Pharmacist) Thy Pham, PharmD (SFHP Clinical Pharmacist) Katrina (Katie) Vo, PharmD (SFHP Clinical Pharmacist) Sue Chan (SFHP Pharmacy Compliance Program Manager) Jason Bamaung, PharmD (MedImpact Therapeutics Pharmacist) Guests: none
Members Absent:	Steven Wozniak, MD	
Meeting Materials:	SFHP Pharmacy & Therapeutics meeting minutes are posted under "Materials" section at https://www.sfhp.org/about-us/committees/pharmacy-and-therapeutics-committee/ SFHP formulary and prior authorization criteria are located at https://www.sfhp.org/providers/pharmacy-services/prior-authorization-requests/	

	Topic	Brought By	Discussion	Action
1.	Call to Order	Steve O'Brien, MD	The meeting was called to order at 7:30 am. - Attendance/Quorum - Agenda overview	Introduction and agenda topics done.
2.	Review and Approval of April 2026 P&T minutes	Steve O'Brien, MD	The committee approved the minutes as presented.	VOTE: <u>Review and Approval of April 2026 P&T minutes</u> Approved minutes as presented. <u>Vote: Unanimous approval (8/8)</u>
3.	Chief Medical Officer and Pharmacy Director Informational Updates	Steve O'Brien, MD Brian Ellsworth, PharmD	- Membership decline trend continues - Medi-Cal reenrollment down across the state. - Work requirements for Medi-Cal eligibility in January	<i>Non-voting item</i>

	Topic	Brought By	Discussion	Action
			- SFHP will review Brown Act for any changes - DSNP line of business expanding, adding clinics this year and next year. - Biosimilar conversion strategy and cost savings update.	
4.	Annual Pharmacy Policies and Procedures (P&Ps) Review	Sue Chan	<i>The plan presented changes to Pharmacy Policies and Procedures (P&P) for P&T committee annual review and approval:</i> Document Changes <u>Pharm-07 Emergency Medication Supply</u> Update: - Update to include monitoring the pharmacy network to ensure a 24-hour pharmacy is in our network. - Updated the name of an affected department due to recent name change from Grievances & Appeals to Appeals & Grievances. <u>Pharm-13 After-Hours Pharmacy Access</u> Update: - Review for retirement. Monitoring of ER prescriptions workflow has been retired. - Pharmacy services have other means in monitoring access to emergency pharmacy services, and it is described in Pharm-07. <u>Pharm-16 Pharmacy Systems User Access</u> Update: - Updated to reflect the number of systems user access is required to be maintained. and set forth the policy - No longer requiring other department to use of the form for access change requests. - Customer Service has been removed from the affected parties section as access is no longer needed. Calls are directed to the PBM or they can reach out to Pharmacy Services. - Updated the title of a position (from Cyber Security Analyst to Cyber Security Supervisor) that receives the quarterly pharmacy systems user access user list and had updated to allow a designee to receive/request. - Other updates were made to reduce redundancies and increase the policy's readability. Committee Discussion: <i>Members confirmed 24-hour pharmacy access monitoring remains active despite Pharm-13 retirement.</i>	VOTE: <u>Review and Approval of Annual Pharmacy Policies and Procedures (P&Ps)</u> Approved recommendations as presented. <u>Vote: Unanimous approval (8/8)</u>
5.	Adjourned to Closed Session	Steve O'Brien, MD	Closed session began at 7:47 am	
6.	Review of Interim Formulary Changes and Formulary Placement for New Drugs to Market	Eileen Kim, PharmD	The plan presented interim formulary changes and formulary status for new drugs to market.	<i>Non-voting item</i>

	Topic	Brought By	Discussion	Action
			<u>Committee Discussion:</u> <i>The plan confirmed there were no anticipated member access concerns identified.</i>	
7.	Review of Interim Utilization Management Changes	Jason Bamaung, PharmD	<i>The plan presented changes to utilization management delegated processes for review.</i> <u>Committee Discussion:</u> <i>The committee had no comments or questions.</i>	<i>Non-voting item</i>
8.	<u>Psychiatry</u> Psychotic Disorders Class Review	Eileen Kim, PharmD Jason Bamaung, PharmD	The plan presented a class review psychiatry medications. <u>Committee Discussion:</u> <i>Dr. O'Brien stated that mental illness diagnosis are among the top diagnosis for our Medi-Cal members and emphasized the importance of these medications for our members.</i>	<i>Non-voting item</i>
9.	<u>Psychiatry</u> Smoking Cessation Class Review	Eileen Kim, PharmD Jason Bamaung, PharmD	The plan presented a class review for psychiatry medications. <u>Committee Discussion:</u> <i>Dr. Ruggiero pointed out that the confidence intervals are very large in the pivotal trial and that is concerning. Dr. Ruiz and Dr. Ruggiero discussed if there is a known association between vaping and increased smoking.</i>	<i>Non-voting item</i>
10.	<u>Cardiology</u> Baxfendy™ (baxdrostat) Monograph	Eileen Kim, PharmD Jason Bamaung, PharmD	The plan presented a monograph for Baxfendy™. <u>Committee Discussion:</u> <i>The committee had no comments or questions.</i>	<i>Non-voting item</i>
11.	<u>Dermatology</u> Adquey™ (difamilast) Monograph	*Deferred due to time constraints*	Discussion of this item was deferred to the next meeting at the recommendation of the committee chair due to time constraints.	<i>Rescheduled for October P&T</i>

	Topic	Brought By	Discussion	Action
12.	<u>Drug Utilization Review (DUR) Reports</u> MedImpact Retrospective Drug Use Evaluation Quarterly Activities 2Q2026	Katie Vo, PharmD	The plan presented the MedImpact rDUE Activities Report for 2Q2026 for committee review. Summary MedImpact's retrospective Drug Use Evaluation program (rDUE) reviews Healthy Workers HMO and Care Plus D-SNP members to promote quality drug therapy for members. Continued monitoring for different areas of rDUE interest will identify any concerning prescribing behavior or possible topics that require further intervention. Materials: - CHF letter - Hyper polypharmacy letter <u>Committee Discussion:</u> <i>The committee agreed that Provider letters are educational quality-improvement tools.</i>	<i>Non-voting item</i>
13.	<u>Drug Utilization Review (DUR) Reports</u> Improving Diabetes Medication Adherence	Thy Pham, PharmD	The plan provided updates diabetes adherence Objectives - Identify the top 3 diabetes drug classes utilized. - Assess adherence in the top diabetes drug classes. - Evaluate 90-day supply (DS) utilization. - Analyze the relationship between 90 DS and adherence. - Identify opportunities to improve diabetes medication adherence. Conclusion - Adherence is multifactorial, no single driver or solution - Focus is on addressing multiple touchpoints: 90 DS RX, mail order, transportation services, follow-up visits, member education - SFHP's Pharmacy Team is actively working to better understand and meet the needs of the care team - Ongoing collaboration and targeted interventions will be key to improving medication adherence <u>Committee Discussion:</u> <i>Discussed PDC limitations, A1C opportunities, GLP-1 barriers, transportation and outreach opportunities.</i>	
14.	<u>DSNP Stars Presentation</u>	Katie Vo, PharmD	The plan provided updates on STARS measures for DSNP for committee review. <u>Committee Discussion:</u> <i>NEMS adherence success and integrated pharmacy-provider partnerships were highlighted.</i>	
15.	Reconvene in Open Session	Steve O'Brien, MD	Open session resumed: 9:17 am.	<i>Non-voting item</i>
16.	Summary of Closed Session	Steve O'Brien, MD	NA- No public attendees.	<i>Non-voting item</i>

	Topic	Brought By	Discussion	Action
17.	<u>Appendix</u> MedImpact Pipeline Report 2Q2026	Jason Bamaung, PharmD	The plan provided information published by MedImpact regarding new developments in the pharmacy market as of 2Q 2026.	<i>Non-voting item</i>
18.	Adjournment	Steve O'Brien, MD	The meeting adjourned at 9:24 am. 2026/2027 P&T Committee Meeting dates are: • Wednesday, October 21, 2026 • Wednesday, January 20, 2027 • Wednesday, April 21, 2027 • Wednesday, July 21, 2027	

Respectfully submitted by:

Steve O'Brien

Steve O'Brien, MD
Pharmacy & Therapeutics Committee Chair

10/21/2026

Date